Updated on 13 May 2015
DKSH will be the sole market expansion services provider for Pfizer's entire range of pharmaceutical products in Laos
Singapore: In a bid to facilitate its expansion into the Southeast Asian nation Laos, global drug giant Pfizer has struck an agreement with DKSH Business Unit, a leading partner for healthcare companies seeking to grow their businesses in Asia.
As per the deal, DKSH will be the sole market expansion services provider for Pfizer's entire range of pharmaceutical products in Laos. The agreement is an extension of the successful regional collaboration that also includes Cambodia and Thailand.
"South East Asian markets such as Laos provide extensive opportunities for multinational companies like Pfizer. With our in-depth industry expertise and nearly 20 years' experience in delivering Market Expansion Services in Laos, we are committed to growing Pfizer's brand in this market," commented, Mr Kentaro Imamoto, General Manager, Business Unit Healthcare, DKSH Laos.
DKSH has a well-established nationwide infrastructure in Laos, well-trained local staff and an in-depth understanding of the Laos healthcare market. The agreement will help in further strengthening DKSH's position in Laos and help in contributing incrementally to the group's overall profitability over time.
"We believe our partnership with DKSH will translate into wider and easier access to our high-quality medicines in Laos, so that more people will benefit from our healthcare innovations. Moreover, their expertise in marketing and sales as well as their dedication to compliance and quality will mean better services to our valued customers and business partners," said Mr Pichitchai Jakpaisan, finance director and Indochina General Manager, Pfizer Thailand.